Comparative Pharmacology
Head-to-head clinical analysis: BUMETANIDE versus ETHACRYNIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUMETANIDE versus ETHACRYNIC ACID.
BUMETANIDE vs ETHACRYNIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Inhibits sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, potassium, and water. Also inhibits prostaglandin degradation.
0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.
50 to 100 mg orally once daily; may increase by 25 to 50 mg increments at intervals of 2 to 3 days up to 400 mg/day. IV: 0.5 to 1 mg/kg slowly (over several minutes); usual initial dose 50 mg.
None Documented
None Documented
Clinical Note
moderateBumetanide + Digoxin
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin."
Clinical Note
moderateBumetanide + Digitoxin
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Digitoxin."
Clinical Note
moderateBumetanide + Deslanoside
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Deslanoside."
Clinical Note
moderateBumetanide + Acetyldigitoxin
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults; prolonged to 1.5-3 hours in renal impairment.
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily renal (approximately 80% as unchanged drug), with minimal biliary/fecal excretion (about 10-20%).
Primarily renal (approximately 60-70% as unchanged drug and metabolites) with some biliary/fecal excretion (approximately 30-40%).
Category A/B
Category C
Loop Diuretic
Loop Diuretic
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Acetyldigitoxin."